{
    "clinical_study": {
        "@rank": "119203", 
        "arm_group": [
            {
                "arm_group_label": "SUF NT 15 mcg", 
                "arm_group_type": "Experimental", 
                "description": "Period 1:  One dose of SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil."
            }, 
            {
                "arm_group_label": "Ketoconazole 400 mg, SUF NT 15 mcg", 
                "arm_group_type": "Experimental", 
                "description": "Ketoconazole 400 mg administered once daily for three days.  One dose of SUF NT 15 mcg was co-administered sublingually with the third (last) ketoconazole dose.\nSubjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil."
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the effect of taking ketoconazole on sufentanil plasma concentrations following\n      sublingual administration of sufentanil NanoTab."
        }, 
        "brief_title": "Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Period 1:  SUF NT 15 mcg administered once sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.\nPeriod 2:  Ketoconazole 400 mg given daily for three days.  One SUF NT 15 mcg was also co-administered sublingually with the third (last) ketoconazole dose.\nSubjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.", 
                        "title": "SUF NT 15 mcg Then 3 Days of Ketoconazole and SUF NT 15 mcg"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "19"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "19"
                                            }
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "description": "Subjects must have been between 18 and 45 years of age, inclusive", 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "11"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "8"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "19"
                                        }
                                    }, 
                                    "sub_title": "United States"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "Requires prior approval from AcelRx Pharmaceuticals, Inc."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "total amount of sufentanil absorbed", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "One SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.", 
                                    "title": "SUF NT 15 mcg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Ketoconazole 400 mg given orally daily for three days.  One SUF NT 15 mcg is also co-administered sublingually with the third (last) ketoconazole dose.\nSubjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.", 
                                    "title": "Ketoconazole 400 mg and SUF NT 15 mcg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "17"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "17"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "46.42", 
                                                        "@value": "126.47"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "45.45", 
                                                        "@value": "223.63"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "total amount of sufentanil absorbed", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "AUC (0-inf)", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "population": "2 of the 19 subjects had incomplete PK data and were excluded from PK analysis (1 due to early withdrawal and 1 due to AE)", 
                        "safety_issue": "No", 
                        "time_frame": "24 hours", 
                        "title": "AUC (0-inf)", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "maximum plasma concentration", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "One SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.", 
                                    "title": "SUF NT 15 mcg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Ketoconazole 400 mg given  daily for three days.  One SUF NT15 mcg is also co-administered sublingually with the third (last) ketoconazole dose.\nSubjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.", 
                                    "title": "Ketoconazole 400 mg and SUF NT 15 mcg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "17"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "17"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "18.57", 
                                                        "@value": "39.95"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "16.50", 
                                                        "@value": "46.00"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "maximum plasma concentration", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Cmax", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "population": "2 of the 19 subjects had incomplete PK data and were excluded from PK analysis (1 due to early withdrawal and 1 due to AE)", 
                        "safety_issue": "No", 
                        "time_frame": "24 hours", 
                        "title": "Cmax", 
                        "type": "Primary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Period 1:  One SUF NT 15 mcg administered sublingually followed by Period 2.\nPeriod 2:  Ketoconazole 400 mg given daily for three days;  One SUF NT 15 mcg was also co-administered sublingually with the third (last) ketoconazole dose.\nSubjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT 15 mcg dosing to block the opioid effects of the sufentanil.", 
                        "title": "SUF NT 15 mcg Followed by Ketoconazole 400 mg + SUF NT 15 mcg"
                    }
                }, 
                "period_list": {
                    "period": [
                        {
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "19", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "19", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "SUF NT 15 mcg"
                        }, 
                        {
                            "drop_withdraw_reason_list": {
                                "drop_withdraw_reason": {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Withdrawal by Subject"
                                }
                            }, 
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "19", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "18", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": {
                                                "@count": "1", 
                                                "@group_id": "P1"
                                            }
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "Ketoconazole 400 mg and SUF NT 15 mcg"
                        }
                    ]
                }
            }, 
            "point_of_contact": {
                "email": "ppalmer@acelrx.com", 
                "name_or_title": "Pamela Palmer, MD, PhD", 
                "organization": "AcelRx Pharmaceuticals, Inc.", 
                "phone": "650-216-3504"
            }, 
            "reported_events": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "One SUF NT 15 mcg administered sublingually.\nSubjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.", 
                            "title": "SUF NT 15 mcg"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Ketoconazole 400 mg given daily for three days.  One SUF NT 15 mcg was also co-administered sublingually with the third (last) ketoconazole dose.\nSubjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.", 
                            "title": "Ketoconazole 400 mg + SUF NT 15 mcg"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "19"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "18"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "19"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "18"
                                            }
                                        ], 
                                        "description": "All adverse events listed on this table are included regardless of relationship to study drug (s)", 
                                        "sub_title": "Photophobia"
                                    }
                                }, 
                                "title": "Eye disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "19"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "18"
                                                }
                                            ], 
                                            "sub_title": "Nausea"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "19"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "18"
                                                }
                                            ], 
                                            "sub_title": "Abdominal Discomfort"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "19"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "18"
                                                }
                                            ], 
                                            "sub_title": "Constipation"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "19"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "18"
                                                }
                                            ], 
                                            "sub_title": "Dyspepsia"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "19"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "18"
                                            }
                                        ], 
                                        "sub_title": "Viral Upper Respiratory Tract Infection"
                                    }
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "19"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "18"
                                            }
                                        ], 
                                        "sub_title": "Myalgia"
                                    }
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "19"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "18"
                                                }
                                            ], 
                                            "sub_title": "Headache"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "19"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "18"
                                                }
                                            ], 
                                            "sub_title": "Lethargy"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "19"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "18"
                                            }
                                        ], 
                                        "sub_title": "Hot Flush"
                                    }
                                }, 
                                "title": "Vascular disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA (11.0)", 
                    "frequency_threshold": "1"
                }, 
                "time_frame": "Four days"
            }
        }, 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Pharmacokinetics", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non smoking\n\n          -  Ages 18 to 45 year, inclusive\n\n          -  BMI between 18 and 30\n\n        Exclusion Criteria:\n\n          -  subjects taking any prescription or OTC medications or vitamins or      supplements\n\n          -  pregnant females\n\n          -  subjects with pulmonary disease or sleep apnea"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "firstreceived_results_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721070", 
            "org_study_id": "IAP104"
        }, 
        "intervention": [
            {
                "arm_group_label": "SUF NT 15 mcg", 
                "description": "Period 1:  One dose of SUF NT 15 mcg administered sublingually", 
                "intervention_name": "Sufentanil NanoTab (SUF NT) 15 mcg", 
                "intervention_type": "Drug", 
                "other_name": "SUF NT 15 mcg"
            }, 
            {
                "arm_group_label": "Ketoconazole 400 mg, SUF NT 15 mcg", 
                "description": "Period 2:  Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day", 
                "intervention_name": "Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg", 
                "intervention_type": "Drug", 
                "other_name": "SUF NT 15 mcg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ketoconazole", 
                "Sufentanil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Area under curve, time to maximum concentration", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lenexa", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66219"
                }, 
                "name": "PRA"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "IAP104 - Assessment of Pharmacokinetic Changes Following Concurrent Administration of Sufentanil NanoTab and Ketoconazole in Healthy Subjects", 
        "overall_official": {
            "affiliation": "AcelRx Pharmaceuticals, Inc.", 
            "last_name": "Pamela P. Palmer, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "total amount of sufentanil absorbed", 
                "measure": "AUC (0-inf)", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "maximum plasma concentration", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721070"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AcelRx Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AcelRx Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}